Urgent global opportunities to prevent birth defects

Seminars in Fetal and Neonatal Medicine

Volumn 19, Issue 3, 2014, Pages 153-160

  Kancherla, Vijaya ^a   Oakley, Godfrey P ^a   Brent, Robert L ^b  

^a EMORY UNIVERSITY   (United States)

^b NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

Author keywords

Birth defects; Congenital abnormalities; Population surveillance; Prevalence; Prevention

Indexed keywords

FOLIC ACID; VALPROIC ACID;

ANENCEPHALUS; BIRTH DEFECT; CONGENITAL RUBELLA SYNDROME; DISEASE ASSOCIATION; DOWN SYNDROME; ENVIRONMENTAL EXPOSURE; FETAL ALCOHOL SYNDROME; GENETIC COUNSELING; HEALTH CARE PERSONNEL; HEALTH PROGRAM; HUMAN; IODINE DEFICIENCY; MATERNAL AGE; MATERNAL DIABETES MELLITUS; NEWBORN HEMOLYTIC DISEASE; PRENATAL SCREENING; PRIMARY PREVENTION; REVIEW; SPINAL DYSRAPHISM; CONGENITAL ABNORMALITIES; FEMALE; HEALTH; NEWBORN; PREGNANCY; PRENATAL DIAGNOSIS;

CONGENITAL ABNORMALITIES; FEMALE; GLOBAL HEALTH; HUMANS; INFANT, NEWBORN; PREGNANCY; PRENATAL DIAGNOSIS;

EID: 84901618092     PISSN: 1744165X     EISSN: 18780946     Source Type: Journal    
DOI: 10.1016/j.siny.2013.11.008     Document Type: Review

References (100)

1. Christianson A., Howson C.P., Modell B. Global report on birth defects 2006, March of Dimes, White Plains, NY.
2. Murray C.J., Lopez A.D. Measuring the global burden of disease. N Engl J Med 2013, 369:448-457.
3. World Health Organization. Global measles and rubella strategic plan: 2012-2020 . http://www.who.int/immunization/newsroom/Measles_Rubella_StrategicPlan_2012_2020.pdf.
4. Progress toward control of rubella and prevention of congenital rubella syndrome - worldwide, 2009. Morb Mortal Wkly Rep 2010, 59:1307-1310. US Centers for Disease Control and Prevention.
5. Metcalf C.J., Lessler J., Klepac P., Cutts F., Grenfell B.T. Impact of birth rate, seasonality and transmission rate on minimum levels of coverage needed for rubella vaccination. Epidemiol Infect 2012, 140:2290-2301.
6. Documentation and verification of measles, rubella and congenital rubella syndrome elimination in the region of the Americas 2012, US Centers for Disease Control and Prevention, United States National Report, CDC, Atlanta.
7. Reef S.E., Redd S.B., Abernathy E., Kutty P., Icenogle J.P. Evidence used to support the achievement and maintenance of elimination of rubella and congenital rubella syndrome in the United States. J Infect Dis 2011, 204:S593-S597.
8. Cutts F.T., Vynnycky E. Modelling the incidence of congenital rubella syndrome in developing countries. Int J Epidemiol 1999, 28:1176-1184.
9. Immunization, vaccines and biologicals - rubella 2012, World Health Organization, WHO, Geneva. http://www.who.int/immunization/topics/rubella/en/index.html.
10. Rubella vaccines: WHO position paper. Wkly Epidemiol Rec 2011, 86:301-316. World Health Organization.
11. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group. Lancet 1991, 338:131-137. Medical Research Council.
12. Honein M.A., Paulozzi L.J., Mathews T.J., Ericson J.D., Wong L.Y. Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. JAMA 2001, 285:2981-2986.
13. De Wals P., Tairou F., Van Allen M.I., Uh S.H., Lowry R.B., Sibbald B., et al. Reduction in neural-tube defects after folic acid fortification in Canada. N Engl J Med 2007, 357:135-142.
14. Hertrampf E., Cortes F., Erickson J.D., Cayazzo M., Freire W., Bailey L.B., et al. Consumption of folic acid-fortified bread improves folate status in women of reproductive age in Chile. J Nutr 2003, 133:3166-3169.
15. Evans S.E., Mygind V.L., Peddie M.C., Miller J.C., Houghton L.A. Effect of increasing voluntary folic acid food fortification on dietary folate intakes and adequacy of reproductive-age women in New Zealand. Public Health Nutr 2013 Jul 9, 1-7. [Epub ahead of print].
16. Bell K.N., Oakley G.P. Tracking the prevention of folic acid-preventable spina bifida and anencephaly. Birth Defects Res A Clin Mol Teratol 2006, 76:654-657.
17. Youngblood M.E., Williamson R., Bell K.N., Johnson Q., Kancherla V., Oakley G.P. 2012 update on global prevention of folic acid-preventable spina bifida and anencephaly. Birth Defects Res A Clin Mol Teratol 2013, 97:658-663.
18. Bhide P., Sagoo G.S., Moorthie S., Burton H., Kar A. Systematic review of birth prevalence of neural tube defects in India. Birth Defects Res A Clin Mol Teratol 2013, 97:437-443.
19. Zhu J., Li X., Wang Y., Mu D., Dai L., Zhou G., et al. Prevalence of neural tube defect pregnancies in China and the impact of gestational age of the births from 2006 to 2008: a hospital-based study. J Matern Fetal Neonatal Med 2012, 25:1730-1734.
20. Zhang L., Ren A., Li Z., Hao L., Tian Y., Li Z. Folate concentrations and folic acid supplementation among women in their first trimester of pregnancy in a rural area with a high prevalence of neural tube defects in Shanxi, China. Birth Defects Res A Clin Mol Teratol 2006, 76:461-466.
21. Oakley G.P. Elimination of folic acid-preventable neural tube defects. Am J Prev Med 2008, 35:606-607.
22. May P.A., Gossage J.P. Estimating the prevalence of fetal alcohol syndrome. A summary. Alcohol Res Health 2001, 25:159-167.
23. May P.A., Gossage J.P., Kalberg W.O., Robinson L.K., Buckley D., Manning M., et al. Prevalence and epidemiologic characteristics of FASD from various research methods with an emphasis on recent in-school studies. Dev Disabil Res Rev 2009, 15:176-192.
24. May P.A., Fiorentino D., Coriale G., Kalberg W.O., Hoyme H.E., Aragon A.S., et al. Prevalence of children with severe fetal alcohol spectrum disorders in communities near Rome, Italy: new estimated rates are higher than previous estimates. Int J Environ Res Public Health 2011, 8:2331-2351.
25. Olivier L., Urban M., Chersich M., Temmerman M., Viljoen D. Burden of fetal alcohol syndrome in a rural West Coast area of South Africa. S Afr Med J 2013, 103:402-405.
26. Viljoen D.L., Gossage J.P., Brooke L., Adnams C.M., Jones K.L., Robinson L.K., et al. Fetal alcohol syndrome epidemiology in a South African community: a second study of a very high prevalence area. J Stud Alcohol 2005, 66:593-604.
27. Urban M., Chersich M.F., Fourie L.A., Chetty C., Olivier L., Viljoen D. Fetal alcohol syndrome among grade 1 schoolchildren in Northern Cape Province: prevalence and risk factors. S Afr Med J 2008, 98:877-882.
28. Tenenbaum A., Hertz P., Dor T., Castiel Y., Sapir A., Wexler I.D. Fetal alcohol spectrum disorder in Israel: increased prevalence in an at-risk population. Isr Med Assoc J 2011, 13:725-729.
29. Elliott E.J., Payne J., Morris A., Haan E., Bower C. Fetal alcohol syndrome: a prospective national surveillance study. Arch Dis Child 2008, 93:732-737.
30. Burns L., Breen C., Bower C., O'Leary C., Elliott E.J. Counting fetal alcohol spectrum disorder in Australia: the evidence and the challenges. Drug Alcohol Rev 2013, 32:461-467.
31. Balachova T., Bonner B., Chaffin M., Bard D., Isurina G., Tsvetkova L., et al. Women's alcohol consumption and risk for alcohol-exposed pregnancies in Russia. Addiction 2012, 107:109-117.
32. May P.A., Gossage J.P., Marais A.S., Adnams C.M., Hoyme H.E., Jones K.L., et al. The epidemiology of fetal alcohol syndrome and partial FAS in a South African community. Drug Alcohol Depend 2007, 88:259-271.
33. Ramsay M. Genetic and epigenetic insights into fetal alcohol spectrum disorders. Genome Med 2010, 2:27.
34. Abel E.L. An update on incidence of FAS: FAS is not an equal opportunity birth defect. Neurotoxicol Teratol 1995, 17:437-443.
35. Alcohol use and binge drinking among women of childbearing age - United States, 2006-2010. Morb Mortal Wkly Rep 2012, 61:534-538. US Centers for Disease Control and Prevention.
36. Rosenthal J., Christianson A., Cordero J. Fetal alcohol syndrome prevention in South Africa and other low-resource countries. Am J Public Health 2005, 95:1099-1101.
37. Williams A.D., Nkombo Y., Nkodia G., Leonardson G., Burd L. Prenatal alcohol exposure in the Republic of the Congo: prevalence and screening strategies. Birth Defects Res A Clin Mol Teratol 2013, 97:489-496.
38. Kim O., Park K. Prenatal alcohol consumption and knowledge about alcohol consumption and fetal alcohol syndrome in Korean women. Nurs Health Sci 2011, 13:303-308.
39. Stoler J.M., Holmes L.B. Under-recognition of prenatal alcohol effects in infants of known alcohol abusing women. J Pediatr 1999, 135:430-436.
40. de Sanctis L., Memo L., Pichini S., Tarani L., Vagnarelli F. Fetal alcohol syndrome: new perspectives for an ancient and underestimated problem. J Matern Fetal Neonatal Med 2011, 24:34-37.
41. Zelner I., Shor S., Lynn H., Roukema H., Lum L., Eisinga K., et al. Neonatal screening for prenatal alcohol exposure: assessment of voluntary maternal participation in an open meconium screening program. Alcohol 2012, 46:269-276.
42. Tough S., Clarke M., Cook J. Fetal alcohol spectrum disorder prevention approaches among Canadian physicians by proportion of Native/Aboriginal patients: practices during the preconception and prenatal periods. Matern Child Health J 2007, 11:385-393.
43. Payne J.M., France K.E., Henley N., D'Antoine H.A., Bartu A.E., O'Leary C.M., et al. RE-AIM evaluation of the Alcohol and Pregnancy Project: educational resources to inform health professionals about prenatal alcohol exposure and fetal alcohol spectrum disorder. Eval Health Prof 2011, 34:57-80.
44. Penrose L.S. The relative effects of paternal and maternal age in Mongolism. J Genet 1933, 27:219-224.
45. Sherman S.L., Allen E.G., Bean L.H., Freeman S.B. Epidemiology of Down syndrome. Ment Retard Dev Disabil Res Rev 2007, 13:221-227.
46. Shin M., Bessler L.M., Kucik J.E., Lu C., Siffel C., Correa A. Prevalence of Down syndrome among children and adolescents in 10 regions of the United States. Pediatrics 2009, 124:1565-1571.
47. Watcham S.J., Schon S., Christianson A.L. Neglect in the care of pregnant South African women of advanced maternal age. S Afr Med J 2007, 97(1064):1068-1069.
48. Boyd P.A., Devigan C., Khoshnood B., Loane M., Garne E., Dolk H., et al. Survey of prenatal screening policies in Europe for structural malformations and chromosome anomalies, and their impact on detection and termination rates for neural tube defects and Down's syndrome. Br J Obstet Gynaecol 2008, 115:689-696.
49. Moise K.J. Fetal anemia due to non-Rhesus-D red-cell alloimmunization. Semin Fetal Neonatal Med 2008, 13:207-214.
50. van der Schoot C.E., Hahn S., Chitty L.S. Non-invasive prenatal diagnosis and determination of fetal Rh status. Semin Fetal Neonatal Med 2008, 13:63-68.
51. Whitfield C.R., Raafat A., Urbaniak S.J. Underreporting of mortality from RhD haemolytic disease in Scotland and its implications: retrospective review. BMJ 1997, 315:1504-1505.
52. Clarke C., Hussey R.M. Decline in deaths from rhesus haemolytic disease of the newborn. J R Coll Physicians Lond 1994, 28:310-311.
53. Greenough A. The role of immunoglobulins in neonatal Rhesus haemolytic disease. BioDrugs 2001, 15:533-541.
54. Lee C.K., Ma E.S., Tang M., Lam C.C., Lin C.K., Chan L.C. Prevalence and specificity of clinically significant red cell alloantibodies in Chinese women during pregnancy - a review of cases from 1997 to 2001. Transfus Med 2003, 13:227-231.
55. Narang A., Jain N. Haemolytic disease of newborn. Indian J Pediatr 2001, 68:167-172.
56. Technology appraisal guidance 41. Guidance on the use of routine antenatal anti-D prophylaxis for RHD-negative women 2002, National Institute of Clinical Excellence, NICE, London.
57. Bettelheim D., Penzer S., Reesink H.W., Csapo B., Pessoa C., Guerra F., et al. Monitoring and treatment of anti-D in pregnancy. Vox Sang 2010, 99:177-192.
58. Osaro E., Charles A.T. Rh isoimmunization in Sub-Saharan Africa indicates need for universal access to anti-RhD immunoglobulin and effective management of D-negative pregnancies. Int J Women's Health 2010, 2:429-437.
59. Natukunda B., Mugyenyi G., Brand A., Schonewille H. Maternal red blood cell alloimmunisation in south western Uganda. Transfus Med 2011, 21:262-266.
60. Mwangi J. Blood group distribution in an urban population of patient targeted blood donors. East Afr Med J 1999, 76:615-618.
61. Jeremiah Z.A. An assessment of the clinical utility of routine antenatal screening of pregnant women at first clinic attendance for haemoglobin genotypes, haematocrit, ABO and Rh blood groups in Port Harcourt, Nigeria. Afr J Reprod Health 2005, 9:112-117.
62. Loua A., Lamah M.R., Haba N.Y., Camara M. Frequency of blood groups ABO and rhesus D in the Guinean population. Transfus Clin Biol 2007, 14:435-439.
63. Tagny C.T., Fongue V.F., Mbanya D. The erythrocyte phenotype in ABO and Rh blood groups in blood donors and blood recipients in a hospital setting of Cameroon: adapting supply to demand. Rev Med Brux 2009, 30:159-162.
64. Eidem I., Stene L.C., Henriksen T., Hanssen K.F., Vangen S., Vollset S.E., et al. Congenital anomalies in newborns of women with type 1 diabetes: nationwide population-based study in Norway, 1999-2004. Acta Obstet Gynecol Scand 2010, 89:1403-1411.
65. Persson M., Norman M., Hanson U. Obstetric and perinatal outcomes in type 1 diabetic pregnancies: a large, population-based study. Diabetes Care 2009, 32:2005-2009.
66. Macintosh M.C., Fleming K.M., Bailey J.A., Doyle P., Modder J., Acolet D., et al. Perinatal mortality and congenital anomalies in babies of women with type 1 or type 2 diabetes in England, Wales, and Northern Ireland: population based study. BMJ 2006, 333:177.
67. Dietz W.H. Overweight in childhood and adolescence. N Engl J Med 2004, 350:855-857.
68. Wong V.W., Suwandarathne H., Russell H. Women with pre-existing diabetes under the care of diabetes specialist prior to pregnancy: are their outcomes better?. Aust NZ J Obstet Gynaecol 2013, 53:207-210.
69. Correa A., Gilboa S.M., Botto L.D., Moore C.A., Hobbs C.A., Cleves M.A., et al. Lack of periconceptional vitamins or supplements that contain folic acid and diabetes mellitus-associated birth defects. Am J Obstet Gynecol 2012, 206(218):e1-13.
70. Mbanya J.C., Motala A.A., Sobnqwi E., Assah F.K., Enoru S.T. Diabetes in sub-Saharan Africa. Lancet 2010, 375:2254-2266.
71. Oakley G.P. Failing to prevent birth defects caused by maternal diabetes mellitus. Am J Obstet Gynecol 2012, 206:179-180.
72. Guerin A., Nisenbaum R., Ray J.G. Use of maternal GHb concentration to estimate the risk of congenital anomalies in the offspring of women with prepregnancy diabetes. Diabetes Care 2007, 30:1920-1925.
73. Mohan V., Seedat Y.K., Pradeepa R. The rising burden of diabetes and hypertension in southeast Asian and African regions: need for effective strategies for prevention and control in primary health care settings. Int J Hypertens 2013, 2013:409083.
74. Bergman M. Inadequacies of current approaches to prediabetes and diabetes prevention. Endocrine 2013, 44:623-633.
75. Dim C.C., Okafor C., Ikeme A.C., Anyahie B.U. Diabetes mellitus in pregnancy: an update on the current classification and management. Niger J Med 2012, 21:371-376.
76. Ali S., Dornhorst A. Diabetes in pregnancy: health risks and management. Postgrad Med J 2011, 87:417-427.
77. Bjerkedal T., Czeizel A., Goujard J., Kallen B., Mastroiacova P., Nevin N., et al. Valproic acid and spina bifida. Lancet 1982, 2:1096.
78. Wyszynski D.F., Nambisan M., Surve T., Alsdorf R.M., Smith C.R., Holmes L.B., et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005, 64:961-965.
79. Morrow J., Russell A., Guthrie E., Parsons L., Robertson I., Waddell R., et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006, 77:193-198.
80. Artama M., Auvinen A., Raudaskoski T., Isojärvi I., Isojärvi J. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology 2005, 64:1874-1878.
81. Kaaja E., Kaaja R., Hiilesmaa V. Major malformations in offspring of women with epilepsy. Neurology 2003, 60:575-579.
82. Kaneko S., Battino D., Andermann E., Wada K., Kan R., Takeda A., et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999, 33:145-158.
83. Vajda F., O'Brien T. Valproic acid use in pregnancy and congenital malformations. N Engl J Med 2010, 363:1771.
84. Werler M.M., Ahrens K.A., Bosco J.L., Mitchell A.A., Anderka M.T., Gilboa S.M., et al. Use of antiepileptic medications in pregnancy in relation to risks of birth defects. Ann Epidemiol 2011, 21:842-850.
85. Harden C.L., Meador K.J., Pennell P.B., Hauser W.A., Gronseth G.S., French J.A., et al. Management issues for women with epilepsy -focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009, 50:1237-1246.
86. Vajda F.J., Horgan D., Hollinworth S., Graham J., Hitchcock A.A., Roten A., et al. The prescribing of antiepileptic drugs for pregnant Australian women. Aust NZ J Obstet Gynaecol 2012, 52:49-53.
87. Glauser T., Ben-Menachem E., Bourgeois B., Cnaan A., Chadwick D., Guerreiro C., et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006, 47:1094-1120.
88. Savica R., Beghi E., Mazzaglia G., Innocenti F., Brignoli O., Cricelli C., et al. Prescribing patterns of antiepileptic drugs in Italy: a nationwide population-based study in the years 2000-2005. Eur J Neurol 2007, 14:1317-1321.
89. Adedinsewo D.A., Thurman D.J., Luo Y.H., Williamson R.S., Odewole O.A., Oakley G.P. Valproate prescriptions for nonepilepsy disorders in reproductive-age women. Birth Defects Res A Clin Mol Teratol 2013, 97:403-408.
90. Gilboa S.M., Broussard C.S., Devine O.J., Duwe K.N., Flak K.L., Boulet S.L., et al. Influencing clinical practice regarding the use of antiepileptic medications during pregnancy: modeling the potential impact on the prevalences of spina bifida and cleft palate in the United States. Am J Med Genet C Semin Med Genet 2011, 157:234-246.
91. Shorvon S.D., Farmer P.J. Epilepsy in developing countries: a review of epidemiological, sociocultural, and treatment aspects. Epilepsia 1988, 29:S36-S54.
92. Padilla C.D., Fagela-Domingo C. Eliminating iodine deficiency: obstacles and their removal. Ann Acad Med Singapore 2008, 37:45-54.
93. Li M., Eastman C.J. The changing epidemiology of iodine deficiency. Nat Rev Endocrinol 2012, 8:434-440.
94. Caldwell K.L., Makhmudov A., Ely E., Jones R.L., Wang R.Y. Iodine status of the U.S. population, National Health and Nutrition Examination Survey, 2005-2006 and 2007-2008. Thyroid 2011, 21:419-427.
95. Obican S.G., Jahnke G.D., Soldin O.P., Scialli A.R. Teratology Public Affairs Committee position paper: iodine deficiency in pregnancy. Birth Defects Res A Clin Mol Teratol 2012, 94:677-682.
96. Leung A.M., Pearce E.N., Braveman L.E. Sufficient iodine intake during pregnancy: just do it. Thyroid 2013, 23:7-8.
97. de Escobar G.M., Obregon M.J., del Rey F.E. Iodine deficiency and brain development in the first half of pregnancy. Public Health Nutr 2007, 10:1554-1570.
98. Pearce E.N. Effects of iodine deficiency in pregnancy. J Trace Elem Med Biol 2012, 26:131-133.
99. Zimmerman M.B., Andersson M. Update on iodine status worldwide. Curr Opin Endocrinol Diabetes Obes 2012, 19:382-387.
100. Brent R.L. The role of the pediatrician in preventing congenital malformations. Pediatr Rev 2011, 32:411.